Title
High-Throughput Assay and Discovery of Small Molecules that Interrupt Malaria Transmission
Date Issued
13 January 2016
Access level
open access
Resource Type
journal article
Author(s)
Plouffe D.M.
Wree M.
Du A.Y.
Meister S.
Li F.
Patra K.
Lubar A.
Okitsu S.L.
Flannery E.L.
Kato N.
Tanaseichuk O.
Comer E.
Zhou B.
Kuhen K.
Zhou Y.
Leroy D.
Schreiber S.L.
Scherer C.A.
Winzeler E.A.
University of California San Diego
Publisher(s)
Cell Press
Abstract
Preventing transmission is an important element of malaria control. However, most of the current available methods to assay for malaria transmission blocking are relatively low throughput and cannot be applied to large chemical libraries. We have developed a high-throughput and cost-effective assay, the Saponin-lysis Sexual Stage Assay (SaLSSA), for identifying small molecules with transmission-blocking capacity. SaLSSA analysis of 13,983 unique compounds uncovered that >90% of well-characterized antimalarials, including endoperoxides and 4-aminoquinolines, as well as compounds active against asexual blood stages, lost most of their killing activity when parasites developed into metabolically quiescent stage V gametocytes. On the other hand, we identified compounds with consistent low nanomolar transmission-blocking activity, some of which showed cross-reactivity against asexual blood and liver stages. The data clearly emphasize substantial physiological differences between sexual and asexual parasites and provide a tool and starting points for the discovery and development of transmission-blocking drugs.
Start page
114
End page
126
Volume
19
Issue
1
Language
English
OCDE Knowledge area
Bioquímica, Biología molecular Enfermedades infecciosas
Scopus EID
2-s2.0-84959473542
PubMed ID
Source
Cell Host and Microbe
ISSN of the container
19313128
Sponsor(s)
We would like to thank Irwin Sherman and Jeremy Burrows for helpful comments, Omar Vandal for support, Paul Willis for chemical analysis, and TropIQ for the SMFA analysis. This work was supported by the Bill & Melinda Gates Foundation ( OPP1040406 to E.A.W. and OPP1032518 to S.L.S.) and the Medicines for Malaria Venture . E.A.W. is supported by grants R01AI103058 and R01AI090141 from NIAID .
Sources of information: Directorio de Producción Científica Scopus